PMID- 37298150
OWN - NLM
STAT- MEDLINE
DCOM- 20230612
LR  - 20230612
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 11
DP  - 2023 May 24
TI  - mTOR Signaling Pathway in Bone Diseases Associated with Hyperglycemia.
LID - 10.3390/ijms24119198 [doi]
LID - 9198
AB  - The interplay between bone and glucose metabolism has highlighted hyperglycemia 
      as a potential risk factor for bone diseases. With the increasing prevalence of 
      diabetes mellitus worldwide and its subsequent socioeconomic burden, there is a 
      pressing need to develop a better understanding of the molecular mechanisms 
      involved in hyperglycemia-mediated bone metabolism. The mammalian target of 
      rapamycin (mTOR) is a serine/threonine protein kinase that senses extracellular 
      and intracellular signals to regulate numerous biological processes, including 
      cell growth, proliferation, and differentiation. As mounting evidence suggests 
      the involvement of mTOR in diabetic bone disease, we provide a comprehensive 
      review of its effects on bone diseases associated with hyperglycemia. This review 
      summarizes key findings from basic and clinical studies regarding mTOR's roles in 
      regulating bone formation, bone resorption, inflammatory responses, and bone 
      vascularity in hyperglycemia. It also provides valuable insights into future 
      research directions aimed at developing mTOR-targeted therapies for combating 
      diabetic bone diseases.
FAU - Wang, Shuangcheng
AU  - Wang S
AD  - State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral 
      Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, 
      China.
FAU - Wang, Jiale
AU  - Wang J
AD  - State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral 
      Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, 
      China.
FAU - Wang, Shuangwen
AU  - Wang S
AD  - West China School of Medicine, Sichuan University, Chengdu 610041, China.
FAU - Tao, Ran
AU  - Tao R
AD  - State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral 
      Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, 
      China.
FAU - Yi, Jianru
AU  - Yi J
AD  - State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral 
      Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, 
      China.
AD  - Department of Orthodontics, West China Hospital of Stomatology, Sichuan 
      University, Chengdu 610041, China.
FAU - Chen, Miao
AU  - Chen M
AUID- ORCID: 0000-0001-6639-7774
AD  - State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral 
      Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, 
      China.
AD  - Department of Orthodontics, West China Hospital of Stomatology, Sichuan 
      University, Chengdu 610041, China.
FAU - Zhao, Zhihe
AU  - Zhao Z
AD  - State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral 
      Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, 
      China.
AD  - Department of Orthodontics, West China Hospital of Stomatology, Sichuan 
      University, Chengdu 610041, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230524
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Humans
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Signal Transduction/physiology
MH  - *Hyperglycemia/complications
MH  - *Diabetes Mellitus
MH  - *Bone Diseases/etiology
MH  - Mammals/metabolism
PMC - PMC10252649
OTO - NOTNLM
OT  - bone complications
OT  - diabetes
OT  - mTOR signaling
COIS- The authors declare no conflict of interest.
EDAT- 2023/06/10 15:14
MHDA- 2023/06/12 06:43
PMCR- 2023/05/24
CRDT- 2023/06/10 01:10
PHST- 2023/04/03 00:00 [received]
PHST- 2023/05/02 00:00 [revised]
PHST- 2023/05/04 00:00 [accepted]
PHST- 2023/06/12 06:43 [medline]
PHST- 2023/06/10 15:14 [pubmed]
PHST- 2023/06/10 01:10 [entrez]
PHST- 2023/05/24 00:00 [pmc-release]
AID - ijms24119198 [pii]
AID - ijms-24-09198 [pii]
AID - 10.3390/ijms24119198 [doi]
PST - epublish
SO  - Int J Mol Sci. 2023 May 24;24(11):9198. doi: 10.3390/ijms24119198.